FDA grants expanded approval for Bristol Myers Squibb anemia therapy - NJBIZ
Descrição
“The approval of Reblozyl in the first-line treatment of anemia for patients with lower-risk MDS represents a crucial step in making transfusion independence possible for more patients," said Tracey Iraca, executive director of the MDS Foundation.
Making a list - NJBIZ
Four NJ entities to lead new pediatric payment model with $15.8M CMS award - NJBIZ
CBRE: Northeast industrial markets demonstrate resiliency - NJBIZ
Bristol Myers Squibb - U.S. FDA Approves Bristol Myers Squibb's Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Who May Require Transfusions
Bristol Myers Squibb - Recent News & Activity
FDA Approves Expansion for BMS' Reblozyl as First-Line Anemia Treatment
Bristol Myers Squibb Stock Falls After Delay to Gene Therapy Drug Approval - Barron's
U.S. FDA approves new Bristol Myers cancer immunotherapy
Young adults, teens one-third of new COVID cases among recent NJ surge - NJBIZ
Lee & Associates New Jersey relocates to Elmwood Park - NJBIZ
Bryan Bloom, Author at NJBIZ
de
por adulto (o preço varia de acordo com o tamanho do grupo)